New and experimental therapies for pulmonary hypertension

R N Channick; L J Rubin

doi:10.1016/s0272-5231(05)70290-2

New and experimental therapies for pulmonary hypertension

Clin Chest Med. 2001 Sep;22(3):539-45. doi: 10.1016/s0272-5231(05)70290-2.

Authors

R N Channick¹, L J Rubin

Affiliation

¹ Department of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California, USA.

PMID: 11590847
DOI: 10.1016/s0272-5231(05)70290-2

Abstract

Advances in the understanding of the molecular and cellular pathogeneses of PPH have led clinicians beyond simple pulmonary vasodilation as the only treatment for PPH and to a realization that what were previously believed to be irreversible vascular lesions may, in fact, be reversible. The development of agents that target the known endothelial and nonendothelial defects in patients with PPH is well underway. Clinicians are witnessing an exciting new era for physicians and patients dealing with this disease.

Publication types

Review

MeSH terms

Animals
Antihypertensive Agents / therapeutic use
Endothelin Receptor Antagonists
Endothelins / therapeutic use
Endothelium, Vascular / physiology
Epoprostenol / analogs & derivatives*
Epoprostenol / therapeutic use
Humans
Hypertension, Pulmonary / drug therapy*
Hypertension, Pulmonary / physiopathology
Nitric Oxide / therapeutic use
Vasodilator Agents / therapeutic use

Substances

Antihypertensive Agents
Endothelin Receptor Antagonists
Endothelins
Vasodilator Agents
Nitric Oxide
beraprost
Epoprostenol
treprostinil